Treatment of hypertension and dyslipidemia (including hypercholesterolemia)
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and the rosuvastatin/ezetimibe combination.
The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended that the tablet be taken at the same time each day (e.g., in the morning), if possible.
Swallow the tablet whole; do not chew, divide, or crush it.
○ Telmisartan/Amlodipine
The recommended dose of the telmisartan/amlodipine combination is once daily.
Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as described below, switching directly to the telmisartan/amlodipine combination may be considered.
- 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg.
- 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or the telmisartan/amlodipine combination 40/5 mg.
- 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg.
◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment.
◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually.
○ Rosuvastatin/Ezetimibe
Patients should follow a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination.
The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response.
Primary hypercholesterolemia
The dose range of the rosuvastatin/ezetimibe combination is 5/10 mg to 20/10 mg once daily. The recommended starting dose is 5/10 mg once daily.
The dose may be adjusted in patients who require a greater reduction in LDL cholesterol. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, blood lipid levels should be checked at intervals of 4 weeks or more, and the dose adjusted accordingly. The dose may be increased up to a maximum of 20/10 mg daily.
For patients taking the telmisartan/amlodipine combination together with the rosuvastatin/ezetimibe combination, switching to this medicine (a combination product with the same amounts of each active ingredient) may be considered for convenience.
Treatment of hypertension and dyslipidemia (including hypercholesterolemia)
Essential hypertension
primary hypercholesterolemia
familial heterozygous hypercholesterolemia
non-familial hypercholesterolemia
mixed dyslipidemia
elevated total cholesterol
elevated LDL cholesterol
elevated Apo B protein
elevated triglycerides
elevated non-HDL cholesterol
View approved original textHide original text
This medication is used for patients who need to take a combination of telmisartan and amlodipine along with a combination of rosuvastatin and ezetimibe. It is primarily prescribed when both hypertension and dyslipidemia need to be treated together. Telmisartan and amlodipine are suitable for patients with essential hypertension who find it difficult to control blood pressure alone, and they help effectively manage blood pressure. Additionally, the combination of rosuvastatin and ezetimibe is used to improve cholesterol levels in patients with primary and mixed dyslipidemia. This medication lowers total cholesterol, LDL cholesterol, Apo B, and triglyceride levels while increasing HDL cholesterol levels, thereby aiding cardiovascular health. Therefore, this medication is used for patients requiring additional control of hypertension and dyslipidemia.
How to take
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and the rosuvastatin/ezetimibe combination.
The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended that the tablet be taken at the same time each day (e.g., in the morning), if possible.
Swallow the tablet whole; do not chew, divide, or crush it.
○ Telmisartan/Amlodipine
The recommended dose of the telmisartan/amlodipine combination is once daily.
Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as described below, switching directly to the telmisartan/amlodipine combination may be considered.
- 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg.
- 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or the telmisartan/amlodipine combination 40/5 mg.
- 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg.
◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment.
◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually.
○ Rosuvastatin/Ezetimibe
Patients should follow a standard cholesterol-lowering diet before and during treatment with the rosuvastatin/ezetimibe combination.
The dose of the rosuvastatin/ezetimibe combination should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response.
Primary hypercholesterolemia
The dose range of the rosuvastatin/ezetimibe combination is 5/10 mg to 20/10 mg once daily. The recommended starting dose is 5/10 mg once daily.
The dose may be adjusted in patients who require a greater reduction in LDL cholesterol. After starting the rosuvastatin/ezetimibe combination or adjusting the dose, blood lipid levels should be checked at intervals of 4 weeks or more, and the dose adjusted accordingly. The dose may be increased up to a maximum of 20/10 mg daily.
For patients taking the telmisartan/amlodipine combination together with the rosuvastatin/ezetimibe combination, switching to this medicine (a combination product with the same amounts of each active ingredient) may be considered for convenience.
Precautions
This medication may cause serious harm to the fetus, especially during the second and third trimesters of pregnancy, so women who are pregnant or may become pregnant should avoid taking it.
Patients with muscle-related diseases or severe liver or kidney dysfunction should not use this medication, and it should not be administered to individuals with allergies to any component of the medication.
Before taking this medication, liver and kidney function tests should be performed, and if abnormalities are found, a doctor should be consulted. Regular tests should also be conducted during treatment.
If symptoms such as muscle pain, weakness, fatigue, or fever occur, a doctor should be notified immediately for examination, and in severe cases, discontinuation of the medication may be necessary.
If blood pressure drops too low or symptoms such as dizziness or fainting occur, it is essential to consult a doctor immediately.
Hyperkalemia (increased potassium levels in the blood) may occur, so potassium levels should be checked regularly, and caution is needed when using potassium supplements or medications containing potassium.
There may be interactions with other medications, so if any other medications are currently being taken, healthcare professionals must be informed, especially with respect to lithium, digoxin, warfarin, and non-steroidal anti-inflammatory drugs.
Caution is required during driving or operating machinery as dizziness or drowsiness may occur.
This medication contains specific pigments and should not be administered to patients with lactose intolerance or certain genetic diseases.
If sudden breathing difficulties or swelling of the face, lips, or tongue occur, the medication should be stopped immediately, and emergency treatment should be sought.
Patients with heart failure or cardiovascular diseases should use this medication cautiously, especially if they have very low blood pressure or weak heart function.
If any unusual symptoms arise during treatment, immediate consultation with a healthcare professional is essential for appropriate action.
Not everyone experiences these, and they can vary from person to person.
Storage
This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the medication's effectiveness.
Appearance and packaging
Appearance
Yellow oval film-coated tablet
Package unit
30 tablets/box [6 tablets/PTP X 5]
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.